TheraSphere Y90 Glass Microspheres 11.5 GBq 990700.SPERecalls & reported problems
Biocompatibles Uk Ltd · TheraSphere Yttrium-90 Glass Microspheres 11.5 GBq Dose · Class 3 · Implant
Data updated Oct 18, 2026 from official FDA records · Editorial policy
- Adverse event reports
- 1
- Deaths reported
- 1
- Injuries reported
- 0
- Recalls naming it
- 0
Summary
The FDA's MAUDE database contains 1 adverse event report that list this exact device (DI 05060116920475), received between Jun 23, 2017 and Jun 23, 2017 — classified as 1 death.
Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 18, 2026.
Most reported problems
Device problems
- Adverse Event Without Identified Device or Use Problem1
Patient problems
- Liver Damage/Dysfunction1
Recent adverse event reports
The 1 most recent of 1 reports, in the reporter's own words as published by the FDA.
DeathJun 23, 2017Adverse Event Without Identified Device or Use Problem; Adverse Event Without Identified Device or Use Problem
(B)(4). SUBJECT (B)(6). LAST SAE REPORT: (B)(6) 2017. SAE: HEPATIC DECOMPENSATION (HEPATIC FAILURE). THIS REPORT CONCERNS SUBJECT (B)(6), A (B)(6) MALE WHO WAS ENROLLED IN STUDY (B)(6) ENTITLED "A PHASE III CLINICAL TRIAL OF INTRA-ARTERIAL THERASPHERE® IN THE TREATMENT OF PATIENTS WITH UNRESPECTABLE HEPATOCELLULAR CARCINOMA (HCC). ON (B)(6) 2016, THE SUBJECT RECEIVED TREATMENT WITH STUDY DEVICE THERASPHERE® TOTAL 117 GY FOR HEPATOCELLULAR CARCINOMA IN THE RIGHT LOBE. ON (B)(6) 2016, THE SUBJECT RECEIVED TREATMENT WITH STUDY DEVICE THERASPHERE® TOTAL 114 GY FOR HEPATOCELLULAR CARCINOMA IN THE LEFT LOBE. ON (B)(6) 2016, THE SUBJECT COMMENCED TREATMENT WITH STANDARD OF CARE THERAPY (SORAFENIB), THE DOSAGE OF WHICH WAS NOT REPORTED AT THE TIME OF REPORTING THIS EVENT. ON (B)(6) 2016, STANDARD OF CARE THERAPY (SORAFENIB) HAS BEEN DISCONTINUED DUE TO LIVER FUNCTION DETERIORATION AND RADIATION HEPATITIS. RELEVANT MEDICAL HISTORY INCLUDED GOUT, DEPRESSION, OESOPHAGEAL VARICES, THROMBOCYTOPENIA, PORTAL HYPERTENSION, FIBROMYALGIA, SERO NEGATIVE ARTHRITIS AND FIRST DEGREE ARTERIO-VENTRICULAR BLOCK. CONCOMITANT MEDICATIONS INCLUDED LANSOPRAZOLE, NAPROXEN, TRAMADOL, FLUOXETINE, AND ALLOPURINOL.
Patient problems: Liver Damage/Dysfunction
MAUDE report 6663506 ↗
Other Microspheres Radionuclide devices
- TheraSphere Administration Set OTT-SPE-FP-001Biocompatibles Uk Ltd · Microspheres Radionuclide2 recalls2 reports
- TheraSphere Administration Set 990226.SPEBiocompatibles Uk Ltd · Microspheres Radionuclide1 recall3 reports
- TheraSphere Y90 Glass Microspheres 3 GBq 990700.SPEBiocompatibles Uk Ltd · Microspheres Radionuclide5 deaths19 reports
- TheraSphere Y90 Glass Microspheres 3.0 GBq (US Commercial) OTT-SPE-FP-700 (990700.SPE)Biocompatibles Uk Ltd · Microspheres Radionuclide13 reports
- SIR-Spheres microspheres SIR-Y001Sirtex Medical Inc. · Microspheres Radionuclide4 deaths11 reports
- TheraSphere Y90 Glass Microspheres 5 GBq 990700.SPEBiocompatibles Uk Ltd · Microspheres Radionuclide1 death8 reports
- TheraSphere Y90 Glass Microspheres 4.0 GBq 990700.SPEBiocompatibles Uk Ltd · Microspheres Radionuclide2 deaths7 reports
- TheraSphere Y90 Glass Microspheres 3.5 GBq 990700.SPEBiocompatibles Uk Ltd · Microspheres Radionuclide1 death6 reports
Sources and updates
- Device record: FDA GUDID, file dated Oct 13, 2026 · View this device in AccessGUDID ↗
- Adverse event reports: FDA MAUDE, file dated Oct 14, 2026 · each report above links to its original FDA record
- Recalls: FDA Medical Device Recalls, file dated Oct 16, 2026
- Page last rebuilt: Oct 18, 2026. Data downloaded through openFDA, which notes it is not validated for clinical or regulatory use.
How reports and recalls are matched · Editorial policy · Report an error on this page